A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Posted on | Posted on John Murphy | Leave a Comment on A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Authors: Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6 Abstract Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial […]

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Authors: Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4 Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed […]

Critics Fault Henry Ford Hydroxychloroquine Study Methodology, Conclusion

Posted on | Posted on John Murphy | Leave a Comment on Critics Fault Henry Ford Hydroxychloroquine Study Methodology, Conclusion

Authors: by Alex McLenon | July 15, 2020 One critic says the study, which found the drug led to fewer COVID-19 deaths, did not used a randomized trial and patients not administered the drug were more likely to die anyway. A recent Henry Ford Health System study finding COVID-19 patients treated with hydroxycloroquine were less likely to die from the virus is drawing skepticism […]

An Update: Is hydroxychloroquine effective for COVID-19?

Posted on | Posted on John Murphy | Leave a Comment on An Update: Is hydroxychloroquine effective for COVID-19?

Authors: Medically reviewed by Drugs.com. Last updated on Feb 2, 2021. Multiple studies provide data that hydroxychloroquine (brand name: Plaquenil) does not provide a medical benefit for hospitalized patients with COVID-19. Hydroxychloroquine, an FDA-approved prescription drug used for malaria, rheumatoid arthritis and lupus erythematosus, has been suggested as a possible treatment or preventive for COVID-19 based […]

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Posted on | Posted on John Murphy | Leave a Comment on Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Authors: COVID-19 Media Briefing with Dr. Adnan Munkarah DETROIT – Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side-effects, according to a new study published by Henry Ford Health System. In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020 across the system’s […]

Peer-Reviewed Publications about COVID-19 (Coronavirus) by Yale Authors

Posted on | Posted on John Murphy | Leave a Comment on Peer-Reviewed Publications about COVID-19 (Coronavirus) by Yale Authors

Sharing knowledge about COVID-19 (coronavirus) is vital to our efforts as we fight the pandemic. Yale researchers are publishing their discoveries about COVID-19 (coronavirus) in peer-reviewed publications. Check back frequently to access the latest findings. Peer-Reviewed COVID-19 Publications from Yale A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?Tuan […]

Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence

Authors: Myron S. Cohen, M.D. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has generated a worldwide pandemic. The interruption of its spread depends on a combination of pharmacologic and nonpharmacologic interventions. Initial SARS-CoV-2 prevention includes social distancing, the use of face masks, environmental hygiene, and hand washing.1 Although […]

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Authors: Philippe Gautret 1, Jean-Christophe Lagier 2, Philippe Parola 1, Van Thuan Hoang 3, Line Meddeb 4, Morgane Mailhe 4, Barbara Doudier 4, Johan Courjon 5, Valérie Giordanengo 6, Vera Esteves Vieira 4, Hervé Tissot Dupont 2, Stéphane Honoré 7, Philippe Colson 2, Eric Chabrière 2, Bernard La Scola 2, Jean-Marc Rolain 2, Philippe Brouqui 2, Didier Raoult 8 Abstract Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads. […]

Adaptive immunity to SARS-CoV-2 and COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Adaptive immunity to SARS-CoV-2 and COVID-19

Authors: Alessandro Sette1,2 and Shane Crotty1,2,* 1Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA2Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA92037, USA SUMMARYThe adaptive immune system is important for control of most viral […]

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Posted on | Posted on John Murphy | Leave a Comment on Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Authors: Alessandro Sette 1 2, Shane Crotty 3 4 Abstract T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, the source and clinical relevance of the reactivity remains unknown. It is speculated that this reflects T cell memory to circulating ‘common cold’ coronaviruses. It will be important to define specificities of these T cells and assess their association […]